Cargando…

The sequence of disease-modifying anti-rheumatic drugs: pathways to and predictors of tocilizumab monotherapy

BACKGROUND: There are numerous non-biologic and biologic disease-modifying anti-rheumatic drugs (bDMARDs) for rheumatoid arthritis (RA). Typical sequences of bDMARDs are not clear. Future treatment policies and trials should be informed by quantitative estimates of current treatment practice. METHOD...

Descripción completa

Detalles Bibliográficos
Autores principales:	Solomon, Daniel H., Xu, Chang, Collins, Jamie, Kim, Seoyoung C., Losina, Elena, Yau, Vincent, Johansson, Fredrik D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7807904/ https://www.ncbi.nlm.nih.gov/pubmed/33446261 http://dx.doi.org/10.1186/s13075-020-02408-4

Ejemplares similares

Predicting Remission Among Patients With Rheumatoid Arthritis Starting Tocilizumab Monotherapy: Model Derivation and Remission Score Development
por: Collins, Jamie E., et al.
Publicado: (2020)

Tocilizumab efficacy and safety in rheumatoid arthritis patients after inadequate response to disease-modifying anti-rheumatic drugs or anti-tumor necrosis factor
por: Abdulkader, Omer Ahmad Fatheddin, et al.
Publicado: (2016)

Safe use of tocilizumab in rheumatic patients with Kaposi's sarcoma
por: Demouche, Sarah, et al.
Publicado: (2022)

Long term effectiveness of RA-1 as a monotherapy and in combination with disease modifying anti-rheumatic drugs in the treatment of rheumatoid arthritis
por: Chopra, Arvind, et al.
Publicado: (2018)

Pilot study of tocilizumab monotherapy for active chronic periaortitis
por: Wang, Anqi, et al.
Publicado: (2023)

Abatacept monotherapy compared with abatacept plus disease-modifying anti-rheumatic drugs in rheumatoid arthritis patients: data from the ORA registry
por: Truchetet, Marie-Elise, et al.
Publicado: (2016)

Marginal Impact of Tocilizumab Monotherapy on Anti-HLA Alloantibodies in Highly Sensitized Kidney Transplant Candidates
por: Daligault, Mélanie, et al.
Publicado: (2021)

Use of Anti-Tumor Necrosis Factor Therapy: A Retrospective Study of Monotherapy and Adherence to Combination Therapy with Non-Biologic Disease-Modifying Anti-Rheumatic Drugs
por: Engel-Nitz, Nicole M., et al.
Publicado: (2015)

Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study
por: Jones, G, et al.
Publicado: (2010)

COVID-19 and Disease-Modifying Anti-rheumatic Drugs
por: D’Silva, Kristin M., et al.
Publicado: (2021)

Tuberculosis in Children with Rheumatic Diseases Treated with Biologic Disease-Modifying Anti-Rheumatic Drugs
por: Kavadichanda, Chengappa, et al.
Publicado: (2021)

Use of the rheumatic drug tocilizumab for treatment of SARS-CoV-2 patients
por: Grygiel-Górniak, Bogna, et al.
Publicado: (2021)

Use of biologic or targeted-synthetic disease-modifying anti-rheumatic drugs and risk of diabetes treatment intensification in patients with rheumatoid arthritis and diabetes mellitus
por: Chen, Sarah K, et al.
Publicado: (2020)

Real-world patient characteristics and use of disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a cross-national study
por: Ingrasciotta, Ylenia, et al.
Publicado: (2022)

Prevalence of coronavirus disease 2019 in rheumatic patients and evaluation of the effect of disease-modifying anti-rheumatic drugs
por: Moradi, Soroush, et al.
Publicado: (2020)

Effectiveness of inactivated influenza vaccine in autoimmune rheumatic diseases treated with disease-modifying anti-rheumatic drugs
por: Nakafero, Georgina, et al.
Publicado: (2020)

Risk of COVID-19 infection in patients with rheumatic disease taking disease-modifying anti-rheumatic drugs
por: Yousefghahari, Behnaz, et al.
Publicado: (2021)

Discriminating phenotypic signatures identified for tocilizumab, adalimumab, and tofacitinib monotherapy and their combinations with methotrexate
por: O’Mahony, Alison, et al.
Publicado: (2018)

Tripterygium wilfordii Hook F versus conventional synthetic disease-modifying anti-rheumatic drugs as monotherapy for rheumatoid arthritis: a systematic review and network meta-analysis
por: Wang, Hai-Long, et al.
Publicado: (2016)

Utilizing biologic disease-modifying anti-rheumatic treatment sequences to subphenotype rheumatoid arthritis
por: Das, Priyam, et al.
Publicado: (2023)

Sustainable Efficacy of Switching From Intravenous to Subcutaneous Tocilizumab Monotherapy in Patients With Rheumatoid Arthritis
por: Ogata, Atsushi, et al.
Publicado: (2015)

Recent Advancements in Drug Delivery of Sinomenine, A Disease-Modifying Anti-Rheumatic Drug
por: Chen, Xin, et al.
Publicado: (2022)

The potential role of 'non-rheumatic’ therapies in rheumatic disease
por: Massarotti, Elena M, et al.
Publicado: (2013)

Comparison of tocilizumab as monotherapy or with add-on disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and inadequate responses to previous treatments: an open-label study close to clinical practice
por: Bykerk, Vivian P., et al.
Publicado: (2015)

Impact of Tocilizumab Monotherapy on Clinical and Patient-Reported Quality-of-Life Outcomes in Patients with Rheumatoid Arthritis
por: Harrold, Leslie R., et al.
Publicado: (2017)

Erratum to: Comparison of tocilizumab as monotherapy or with add-on disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and inadequate responses to previous treatments: an open-label study close to clinical practice
por: Bykerk, Vivian P., et al.
Publicado: (2015)

Evaluation of a patient decision aid for initiating disease modifying anti-rheumatic drugs
por: Nota, Ingrid, et al.
Publicado: (2016)

Psoriatic Arthritis and Metabolic Syndrome: Is There a Role for Disease Modifying Anti-Rheumatic Drugs?
por: Atzeni, Fabiola, et al.
Publicado: (2021)

Potential of Disease-Modifying Anti-Rheumatic Drugs to Limit Abdominal Aortic Aneurysm Growth
por: Thanigaimani, Shivshankar, et al.
Publicado: (2022)

Effectiveness of sequential biologic and targeted disease modifying anti-rheumatic drugs for rheumatoid arthritis
por: Zhao, Sizheng Steven, et al.
Publicado: (2022)

An update on the use of conventional and biological disease-modifying anti-rheumatic drugs in hand osteoarthritis
por: Tenti, Sara, et al.
Publicado: (2023)

Disease-modifying anti-rheumatic drugs improve the cardiovascular profile in patients with rheumatoid arthritis
por: Giachi, Andrea, et al.
Publicado: (2022)

Intestinal microsporidiosis: a hidden risk in rheumatic disease patients undergoing anti-tumor necrosis factor therapy combined with disease-modifying anti-rheumatic drugs?
por: Aikawa, Nadia Emi, et al.
Publicado: (2011)

Chronic conventional disease-modifying anti-rheumatic drugs masking severe SARS-CoV-2 manifestations in an elderly rheumatic patient
por: Sagnelli, Caterina, et al.
Publicado: (2020)

Phase III Study of the Efficacy and Safety of Subcutaneous Versus Intravenous Tocilizumab Monotherapy in Patients With Rheumatoid Arthritis
por: Ogata, Atsushi, et al.
Publicado: (2014)

Predictors of Mortality in Tocilizumab-Treated Severe COVID-19
por: Pagkratis, Konstantinos, et al.
Publicado: (2022)

The Effect of Anti-rheumatic Drugs on the Skeleton
por: Hauser, B., et al.
Publicado: (2022)

Effect of disease-modifying anti-rheumatic drugs on bone structure and strength in psoriatic arthritis patients
por: Simon, David, et al.
Publicado: (2019)

Effect of biologics and targeted synthetic disease-modifying anti-rheumatic drugs on fatigue in rheumatoid arthritis
por: Choy, Ernest H
Publicado: (2019)

Therapeutic Utility and Adverse Effects of Biologic Disease-Modifying Anti-Rheumatic Drugs in Inflammatory Arthritis
por: Min, Hong Ki, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_u56coi6narmqn1o5l06k3486ja